Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. Talphera's management will be available for one-on-one meetings during the conference.

The company's presentation will be accessible on-demand starting September 9 at 7:00 AM ET. Interested parties can view the presentation through a provided link or by visiting the Investors section of Talphera's website at www.talphera.com. The webcast link can be found in the Investors/News & Events/Upcoming Events section.

News Market Reaction – TLPH

-1.98%

1 alert

-1.98% News Effect

On the day this news was published, TLPH declined 1.98%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN MATEO, Calif., Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26^th Annual Global Investment Conference and will be taking 1x1 meetings.

The conference is being held on September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, and the presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302239931.html

SOURCE Talphera, Inc.

FAQ

When is Talphera (TLPH) participating in the H.C. Wainwright Global Investment Conference?

Talphera (TLPH) is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.

Where can I watch Talphera's (TLPH) presentation from the H.C. Wainwright conference?

Talphera's (TLPH) presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET on their website www.talphera.com in the Investors/News & Events/Upcoming Events section.

Will Talphera (TLPH) be offering one-on-one meetings at the H.C. Wainwright conference?

Yes, Talphera (TLPH) management will be available for one-on-one meetings during the H.C. Wainwright 26th Annual Global Investment Conference.

What is the venue for the H.C. Wainwright conference where Talphera (TLPH) is participating?

The H.C. Wainwright 26th Annual Global Investment Conference is being held at the Lotte New York Palace Hotel in New York City.